ClinicalTrials.gg
TerminatedNCT00619151Updated Nov 16, 2011Results posted

CarboMedics Top Hat vs St. Jude Medical Regent Valve Comparing Sizing and Hemodynamics

An interventional study of Top Hat and Regent in Aortic Valve Disease, sponsored by Sorin Group USA, Inc.. Terminated at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-11-16.

Sponsored by Sorin Group USA, Inc. (part of LivaNova) · Not applicable and Interventional

Why this study was terminated
Study stopped due to lack of elegible patient enrollment
Phase
Not applicable
Study type
Interventional
Enrollment
2
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to compare the sizing and implant techniques between the CarboMedics Top Hat supra-annular valve and the St. Jude Medical Regent valve.

02

Conditions studied

  • Aortic Valve Disease

Browse trials for

Keywords

  • aortic valve
  • heart valve
  • valve replacement
  • Valve disease
03

In context

Aortic Valve Disease

234 studies on the registry are indexed under Aortic Valve Disease; 75 are open to participants now.

This study's enrollment of 2 is below the median of 107 across 119 interventional studies indexed under Aortic Valve Disease.

Browse Aortic Valve Disease studies →

Lead sponsor

Sorin Group USA, Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.

First submitted before Sorin Group USA, Inc. became part of LivaNova.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who are indicated for implant with a mechanical valve prosthesis in the aortic position according to the current practice for valve selection at the center.

Exclusion criteria

Exclusion Criteria:

  • Patients \< 18 years of age
  • Emergency surgery
  • Pre-existing valve prosthesis
  • Aortic root replacement
  • Active endocarditis
05

Study design

Phase
Not applicable
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2 participants (actual)

Study arms

  • Active comparator
    1

    CarboMedics Supra-annular Top Hat Valve

    Device: Top Hat

  • Active comparator
    2

    St. Jude Medical Regent Valve

    Device: Regent

Interventions

  • DeviceTop Hat

    Implant of CarboMedics Top Hat mechanical valve.

  • DeviceRegent

    Implant of the St. Jude Medical Regent mechanical valve

06

What researchers measure

Primary outcomes

  1. Effective Orifice Area (EOA)

    Effective Orifice Area of the prosthetic valve measured via echocardiography to determine physiological area of blood flow through the valve.

    Time frame: 6 month evaluation

  2. Aortic Mean Gradient

    Mean gradient measured across the aortic prosthetic valve via echocardiography to determine mean pressure of blood flow across the valve.

    Time frame: 6 months

07

Results

Posted Nov 3, 2011
Limitations and caveats
Early termination due to low enrollment resulted in only 2 patients. Insufficient data for analysis.

Participant flow

Participant flow — Overall Study
MilestoneTop Hat ValveSt.Jude Valve
Started20
Completed10
Not completed10
Withdrew: Study terminated prior to followup10

Outcome measures

PrimaryEffective Orifice Area (EOA)

Effective Orifice Area of the prosthetic valve measured via echocardiography to determine physiological area of blood flow through the valve.

Time frame:
6 month evaluation
Reported as:
Mean · cm^2

No measurements were reported for this outcome.

PrimaryAortic Mean Gradient

Mean gradient measured across the aortic prosthetic valve via echocardiography to determine mean pressure of blood flow across the valve.

Time frame:
6 months
Reported as:
Mean · mmHg

No measurements were reported for this outcome.

Adverse events

Collected over Duration of hospital stay after surgery, an average of 4 days.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Top Hat Valve—0/2 (0%)0/2 (0%)
St.Jude Valve———

Baseline characteristics

Age, Customized
Age, Customized(participants)Top Hat ValveSt.Jude ValveTotal
<18 years0—0
>= 18 years2—2
Sex/Gender, Customized
Sex/Gender, Customized(participants)Top Hat ValveSt.Jude ValveTotal
Unknown2—2
FemaleNA——
MaleNA——
Region of Enrollment
Region of Enrollment(participants)Top Hat ValveSt.Jude ValveTotal
United States2—2
08

Study locations

2 sites
  • Johns Hopkins Hospital
    Baltimore, Maryland 21287, United States
  • Wellmont Holston Valley Medical Center
    Kingsport, Tennessee 37660, United States
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 16, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00619151
Responsible party
Sponsor
First posted
Feb 20, 2008
Start date
Dec 2007
Primary completion
May 2008
Completion
May 2008
Results posted
Nov 3, 2011
Last update
Nov 16, 2011

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion